ESTRO 2024 - Abstract Book

S1807

Clinical - Lung

ESTRO 2024

Results:

Of the 68 eligible patients, median age was 73 yrs (range 50-90). Non-small cell lung cancer was the most prominent primary tumour (n=62), followed by colorectal (n=8), cervix (n=1), and renal (n=1). The median tumour volume reached 12.40cc (ranging from 1.24 to 77.30cc). The median maximum dose (Dmax 0.5cc) to the trachea and bronchus was recorded to be 23.2Gy (0.7-59.5Gy range). The median follow-up period lasted 16 months (spanning from 1-67), with a projected median OS of 39 months and an OS at the 12-month mark of 82%. Recorded toxicity rates remained low, with grade 1 toxicity including fatigue and grade 2 comprising of cough and dyspnoea. Importantly, no evidence was detected for grade 3 or higher toxicities.

Conclusion:

Our study substantiates existing literature conclusions by demonstrating that the utilization of SABR for central lung tumours yields acceptable overall survival rates and manageable post-radiotherapy toxicity levels. Elevated grade toxicities were not evident, thereby underscoring the safety and practicality of this treatment approach.

Keywords: SABR, Central Lung Tumours

References:

Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun;16(6):630-7. doi: 10.1016/S1470-2045(15)70168-3. Epub 2015 May 13. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427. PMID: 25981812; PMCID: PMC4489408.

3098

Digital Poster

First-in-Human Experience with Biology-guided Radiotherapy (BgRT) Using the RefleXion X1 System

Murat Surucu, Nikhil V Kotha, Daniel Pham, Nataliya Kovalchuk, Bin han, Billy W Loo Jr, Lucas K Vitzthum

Stanford University, Radiation Oncology, Stanford, USA

Purpose/Objective:

Biology-guided radiotherapy (BgRT) or SCINTIX is an innovative methodology that guides radiation therapy using the live positron emission tomography (PET) captured during radiation delivery. The RefleXion X1 radiotherapy system